Gregory J Opiteck
Vice President, Translational Medicine Janux Therapeutics
Gregory J Opiteck is Head of Translational Medicine and Vice President at Janux Therapeutics, a role he joined in 2026. Previously, he led precision and translational medicine at Affini-T Therapeutics, Allogene Therapeutics, Gossamer Bio and Receptos (a Celgene subsidiary), and held senior roles at Merck, Caprion Pharmaceuticals and Bristol-Myers Squibb.
Seminars
Thursday 18th March 2027
Chair’s Opening Remarks
8:20 am
